Ferritin: Sex- and Cycle-Related Differences, Normal Ranges, and Optimal Targets

Ferritin is the body's iron storage protein, measured in serum as a proxy for total-body iron reserves (ng/mL, equivalent to mcg/L). It is a distinct test from serum iron, transferrin saturation, and total iron-binding capacity (TIBC), and it behaves differently from all three because it also rises during inflammation. This article covers serum ferritin specifically, not hemoglobin or hematocrit, and focuses on how sex, menstrual cycling, and reproductive hormones change what a given ferritin number means.

Direct answer: Standard laboratory reference ranges for ferritin (roughly 12 to 150 ng/mL in women and 24 to 336 ng/mL in men, with variation by lab) are population-derived cutoffs for detecting overt iron deficiency, not thresholds for symptom resolution or optimal tissue iron-enzyme function. Premenopausal women run substantially lower than men because of recurring menstrual iron loss, ferritin can fall meaningfully during and just after menstruation, and several specialty guideline groups (notably for restless legs syndrome) use functional treatment thresholds well above standard lab "low" cutoffs. A ferritin result that prints as normal on a lab report does not rule out clinically relevant iron depletion, particularly when inflammation is present.

Why women run lower than men

Three mechanisms explain the sex gap in ferritin, and they matter for different reasons.

Menstrual blood loss. Each cycle removes iron directly from the body, and the amount varies widely between individuals depending on flow volume and duration. Women with heavy menstrual bleeding lose considerably more iron per cycle than women with average flow, and average dietary iron absorption is too low to reliably offset heavy losses through food alone. This is the dominant driver of the sex difference in ferritin and is well established physiology, though the specific loss figures sometimes cited in clinical materials (for example, exact milligrams per cycle) vary by source and should be treated as approximate.

Estrogen's modest effect. Estrogen has been reported to mildly increase intestinal iron absorption, but this effect is not large enough to close the gap created by menstrual loss. The clinically relevant pattern is that ferritin tends to rise once menstrual losses decrease or stop (contraceptive suppression of bleeding, or menopause), not that estrogen itself substantially boosts iron stores while cycling continues.

Testosterone and erythropoiesis. Testosterone stimulates red blood cell production, which increases the body's use of iron as red cell mass expands. This is why men beginning testosterone replacement therapy (TRT) commonly show rising hemoglobin alongside falling ferritin over the following months, and why clinicians prescribing TRT typically check a baseline iron panel and recheck around three months. A meaningful ferritin drop in that window, even without frank anemia, is a common enough finding that it deserves discussion with the prescribing clinician rather than being dismissed as noise.

Ferritin is also an inflammation marker, not just an iron marker

Because the liver increases ferritin production during inflammation, a ferritin result can look "normal" or even elevated in someone whose true iron stores are depleted, if they also have an infection, active autoimmune disease, or significant metabolic inflammation. Clinical practice generally addresses this by interpreting ferritin alongside C-reactive protein (CRP): a ferritin in the 30 to 50 ng/mL range paired with a clearly elevated CRP may still represent functionally low iron stores, and this pattern deserves clinical interpretation rather than reassurance based on the ferritin number alone. The exact correction factor sometimes quoted for how much CRP elevation inflates ferritin varies across sources and should be confirmed against current inflammation-adjusted iron deficiency guidance before being stated as a fixed percentage.

How the menstrual cycle shifts ferritin

Ferritin levels fluctuate throughout the menstrual cycle. Ferritin typically drops during menstruation and early follicular phase, then rebounds over the next one to two weeks as blood loss is replaced. This timing effect has clinical relevance: a ferritin test on cycle day 2 or 3 may yield substantially lower values than a mid-cycle test in the same person, despite both falling within the laboratory's reference range. To obtain more stable, interpretable results in menstruating individuals, ferritin should ideally be drawn between cycle day 7 and day 21, with the cycle day documented on the lab order. The exact size of the ferritin decline from mid-cycle to menses cited in small studies (typically described as a 20 to 25 percent decrease) remains unverified for this article and should be confirmed in primary sources before citing specific percentages.

In women with heavy menstrual bleeding, this cycle-driven dip can push an already marginal ferritin into single digits during the first days of a period, which is one reason clinicians evaluating unexplained fatigue or hair shedding in women with heavy periods often ask about the timing of the blood draw before concluding iron status is adequate.

What "optimal" means for specific symptoms

Standard lab reference ranges were built to flag overt deficiency, not to define the ferritin level at which iron-dependent tissues function best. Several specialty areas have developed their own working thresholds, and these are worth separating from the general population range.

Hair shedding. Iron is a cofactor for enzymes involved in hair follicle cycling, and low ferritin has long been discussed as a contributor to telogen effluvium and to worsening of female pattern hair loss. Dermatology literature has associated ferritin below roughly 40 ng/mL with follicle-cycle disruption, and hair-loss specialists in practice often prefer to see ferritin closer to 70 to 100 ng/mL before ruling iron out as a contributing factor. This is a clinical practice pattern built on observational associations, not a single definitive trial, and should be described to patients as such.

Restless legs syndrome (RLS). Dopamine synthesis in the brain is iron-dependent, and international RLS guideline work has recommended checking ferritin in patients with RLS symptoms and treating iron deficiency at ferritin levels well above the standard "low" cutoff, generally citing a threshold in the range of 75 ng/mL, with oral iron favored above roughly 50 ng/mL and intravenous iron considered below that level for moderate-to-severe symptoms. This is guideline-level evidence for a specific patient population (confirmed RLS), not a general population target, and the exact numeric thresholds should be checked against the current published guideline text before being used clinically.

Thyroid function. Thyroid peroxidase, the enzyme that helps make thyroid hormone, requires iron as a cofactor. Observational studies have linked lower ferritin with a higher likelihood of subclinical hypothyroidism in some populations. This is an association, not proof that correcting ferritin alone normalizes thyroid function, and it is a reasonable factor to raise with a clinician in a workup for fatigue or cold intolerance with borderline thyroid labs, not a reason to self-treat.

A note on "longevity medicine" targets. Ranges in the 70 to 100 ng/mL (premenopausal women) and 100 to 150 ng/mL (men and postmenopausal women) territory circulate widely in functional and longevity medicine as general wellness targets. These numbers are a synthesis of the symptom-specific thresholds above rather than a single validated target range from a major medical society, and readers should understand them as a practice pattern used by some clinicians, not an established guideline.

Postmenopausal shift and when high ferritin needs a workup

Ferritin tends to rise substantially after menopause as monthly blood loss stops, and postmenopausal women's ranges gradually move closer to typical male ranges over the following years. Two practical points follow from this. First, a postmenopausal woman with a ferritin result that would look unremarkable in a 25-year-old (for example, in the mid-30s ng/mL) may actually be iron-deficient relative to her expected post-menopausal range, which is a reason to ask about occult gastrointestinal blood loss rather than assume the number is fine because it's "normal." Second, ferritin that climbs well above typical ranges without an inflammatory explanation, roughly above 300 ng/mL in men or above 200 ng/mL in women, warrants investigation. The standard differential includes hereditary hemochromatosis (HFE gene variants), non-alcoholic fatty liver disease, chronic inflammatory disease, and, at very high levels (into the thousands), rarer causes such as adult-onset Still's disease or hemophagocytic lymphohistiocytosis. Genetic testing for HFE variants is generally considered when ferritin is elevated together with a high transferrin saturation, and this decision belongs with a clinician who can order and interpret the full iron panel together.

Hormonal contraception and hormone therapy

Combined oral contraceptives reduce menstrual blood loss for most users, and reduced bleeding is generally expected to raise ferritin over months of use. The reverse is also worth anticipating: women who stop a combined pill and resume heavier natural cycles can see ferritin decline again over the following months, which is a reasonable thing to flag if fatigue or hair shedding develops after stopping contraception.

Estrogen-containing hormone therapy in postmenopausal women has been reported to modestly blunt the post-menopausal rise in ferritin, plausibly through mild plasma volume expansion and effects on iron handling. The effect described in observational cohort data is modest and does not typically change how ferritin should be interpreted or managed in someone on hormone therapy.

Testosterone therapy in women, at the low doses typically used for androgen deficiency, has not been shown to reliably produce the erythropoietic effect seen in men on standard TRT doses, though higher-dose formulations (such as certain pellet regimens) have been associated with measurable hemoglobin increases in some patients, which is a reasonable prompt for a follow-up iron panel a few months in.

Diagnosing iron deficiency: ferritin in context

Ferritin alone should not carry a diagnosis of iron deficiency. A complete iron evaluation typically includes serum ferritin, serum iron, TIBC, and transferrin saturation (serum iron divided by TIBC). Two patterns are commonly distinguished in clinical practice:

• Iron deficiency without anemia: low-normal or low ferritin (commonly a cutoff near 30 ng/mL is used), low transferrin saturation, and normal hemoglobin. Cardiology guidance for patients with heart failure has used ferritin thresholds around 100 ng/mL (or 100 to 299 ng/mL with reduced transferrin saturation) to decide on treatment, which illustrates how much higher a "treat" threshold can be in a symptomatic population compared with a general population reference range.
• Iron deficiency anemia: ferritin typically below 15 ng/mL combined with hemoglobin below the WHO-referenced thresholds for anemia (commonly cited as below 12 g/dL in women and below 13 g/dL in men, though exact WHO cutoffs vary by age, pregnancy status, and the specific WHO document referenced, and should be confirmed against current WHO guidance for the population in question).

Oral iron repletion for confirmed deficiency generally takes months, not weeks. Alternate-day dosing has been studied as a way to improve absorption relative to daily dosing, based on how iron intake acutely raises the regulatory hormone hepcidin and temporarily blunts further absorption for roughly a day; this is a reasonable topic to raise with a prescriber rather than a self-directed dosing decision, since individualized dosing is outside the scope of this article. Intravenous iron (for example, ferric carboxymaltose, an FDA-approved option for patients who cannot tolerate or adequately absorb oral iron) can restore ferritin much faster than oral repletion and is generally reserved for more severe deficiency, malabsorption, or intolerance of oral iron, under a clinician's direction.

Evidence boundary: what is established, what is not

Established: Ferritin reflects iron stores and is lower on average in premenopausal women than in men, primarily because of menstrual blood loss. Ferritin behaves as an acute-phase reactant and can be falsely reassuring during inflammation. Ferritin rises after menopause and with reduced menstrual bleeding (including on combined contraceptives). Very high ferritin without inflammation warrants a workup for hemochromatosis and related conditions. The WHO hemoglobin-based definition of anemia and the general iron-panel diagnostic pattern (ferritin, iron, TIBC, transferrin saturation) are standard clinical practice.

Plausible but not firmly established at a population level: Specific numeric "optimal" ferritin targets (70 to 100 ng/mL, 100 to 150 ng/mL) used in functional and longevity medicine are a clinical practice pattern extrapolated from symptom-specific and guideline-specific thresholds, not a single validated general-population target endorsed by a major medical body. The exact magnitude of cycle-phase ferritin swings, the precise inflation of ferritin caused by a given CRP elevation, and several other specific percentages referenced in popular ferritin content circulate widely but were not independently verifiable from the sources available for this draft and should be confirmed against the primary literature before publication.

Not established: That raising ferritin into the "optimal" range causes resolution of hair loss, fatigue, or thyroid symptoms in people without confirmed iron deficiency. Iron supplementation in someone who is not iron deficient carries its own risks (including, at the extreme, iron overload) and is not supported as a general wellness intervention.

A decision framework for interpreting your own ferritin result

Use this to organize a conversation with a clinician, not to self-diagnose or self-dose.

If your situation does not fit cleanly into one of these rows, for example ferritin fluctuating widely between two labs, or symptoms persisting despite an "optimal" ferritin, that mismatch itself is a reason for a clinical visit rather than continued self-monitoring.

When to seek care rather than retest at home

Very high ferritin (particularly with joint pain, unexplained liver enzyme elevation, or a family history of hemochromatosis), ferritin in the single digits with symptoms of significant anemia (shortness of breath, chest pain, fainting), or heavy menstrual bleeding with fatigue should prompt a clinical visit rather than a repeat home or direct-to-consumer lab draw. Iron supplementation dosing, IV iron eligibility, and genetic testing decisions require an individualized clinical assessment that this article cannot provide.

A note on sourcing for this draft: Automated primary-source discovery for this topic did not return verifiable citations, and several numeric identifiers in the prior version of this article pointed to papers that do not clearly support the claims attached to them. Where a specific number or study result could not be confirmed against accessible primary literature, this draft has stated the underlying clinical concept while flagging the number as needing verification rather than presenting it as settled. Editorial and clinical review should confirm exact thresholds (particularly the RLS ferritin cutoff, the WHO anemia hemoglobin cutoffs for the relevant population, and any cycle-phase percentage figures) against current primary sources before publication.